Eli Lilly and Company announced that the U.S. FDA has approved a new use for its osteoporosis drug FORTEO [teriparatide injection] to treat osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture.
The details can be read here.
No comments:
Post a Comment